Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
pembrolizumab vs nivolumab mechanism | 0.16 | 0.9 | 9825 | 52 | 36 |
pembrolizumab | 0.93 | 0.1 | 5550 | 82 | 13 |
vs | 1.74 | 0.9 | 4495 | 50 | 2 |
nivolumab | 1.35 | 0.9 | 5822 | 47 | 9 |
mechanism | 1.2 | 0.4 | 1861 | 95 | 9 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
pembrolizumab vs nivolumab mechanism | 1.13 | 0.8 | 1527 | 90 |
nivolumab and pembrolizumab combination | 1.4 | 0.4 | 8110 | 8 |
pembrolizumab vs nivolumab melanoma | 1.76 | 0.4 | 5278 | 44 |
ipilimumab and nivolumab vs pembrolizumab | 0.95 | 0.2 | 4121 | 97 |
nivolumab pembrolizumab and atezolizumab | 0.44 | 0.1 | 49 | 15 |
pembrolizumab versus nivolumab for melanoma | 1.8 | 0.9 | 296 | 34 |
pembrolizumab mechanism of action | 0.89 | 0.8 | 2541 | 24 |
nivolumab and pembrolizumab for lung cancer | 1.78 | 0.5 | 8584 | 6 |
nivolumab and pembrolizumab side effects | 1.81 | 0.5 | 8094 | 92 |
pembrolizumab mechanism of action youtube | 1.59 | 1 | 4581 | 17 |
pembrolizumab mechanism of action ppt | 1.46 | 0.2 | 1275 | 87 |
nivolumab and pembrolizumab for mesothelioma | 1.04 | 0.4 | 692 | 86 |
pembrolizumab how it works | 1.58 | 0.4 | 41 | 65 |
pembrolizumab target mechanism of action | 1.88 | 1 | 3888 | 50 |
pembrolizumab mode of action | 1.24 | 0.8 | 3586 | 17 |
pembrolizumab-induced | 1.44 | 0.5 | 1526 | 6 |
pembrolizumab in combination with | 0.92 | 0.7 | 711 | 66 |
does pembrolizumab cause immunosuppression | 0.21 | 0.5 | 6083 | 3 |
pembrolizumab patient information leaflet | 1.22 | 0.9 | 452 | 7 |